Supriya Lifescience Limited has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a substantial increase in revenue from operations, reaching ₹1,897.47 million, a significant jump from the previous year’s corresponding quarter. Profit before tax also saw a healthy rise, reflecting strong operational performance and market demand for its products.
Strong Quarterly Performance Reported
Supriya Lifescience Limited has declared its unaudited financial results for the quarter that concluded on June 30, 2026. The company showcased a robust performance with its Revenue from Operations amounting to ₹1,897.47 million. This figure represents a significant increase when compared to the ₹778.73 million reported for the quarter ended June 30, 2025. This substantial growth underscores the company’s expanding market presence and operational efficiency.
Profitability and Earnings Growth
The company’s total income for the quarter reached ₹1,923.95 million. Following the reporting of expenses, which totaled ₹1,516.03 million, Supriya Lifescience posted a Profit Before Tax (PBT) of ₹407.92 million for the period. After accounting for tax expenses, the Net Profit for the period from Continuing Operations stood at ₹240.43 million. Earnings per equity share (basic and diluted) for the continuing operations were reported at ₹2.99 for the quarter.
Comprehensive Income and Key Notes
Total Comprehensive Income for the quarter amounted to ₹246.90 million. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and were reviewed by the Audit Committee and approved by the Board of Directors on August 13, 2026. A note highlighted that goods dispatched for export were detained by Customs but were recognized as sales since shipment had reached Customs for processing.
Source: BSE
